Li Watsek
Stock Analyst at Cantor Fitzgerald
(2.40)
# 2,490
Out of 5,124 analysts
78
Total ratings
51.85%
Success rate
-2.35%
Average return
Main Sectors:
Top Industries:
Stocks Rated by Li Watsek
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| AVBP ArriVent BioPharma | Initiates: Overweight | n/a | $20.12 | - | 1 | Dec 23, 2025 | |
| CMPX Compass Therapeutics | Initiates: Overweight | n/a | $5.37 | - | 1 | Dec 3, 2025 | |
| ASND Ascendis Pharma | Maintains: Overweight | $203 → $254 | $213.24 | +19.11% | 20 | Oct 13, 2025 | |
| CNTX Context Therapeutics | Initiates: Overweight | n/a | $1.47 | - | 1 | Oct 2, 2025 | |
| IDYA IDEAYA Biosciences | Reiterates: Overweight | n/a | $34.57 | - | 3 | Sep 9, 2025 | |
| REPL Replimune Group | Upgrades: Overweight | n/a | $9.72 | - | 2 | Jul 30, 2025 | |
| KURA Kura Oncology | Reiterates: Overweight | n/a | $10.39 | - | 11 | Jun 26, 2025 | |
| ZLAB Zai Lab | Reiterates: Overweight | n/a | $17.64 | - | 1 | Mar 27, 2025 | |
| ACRV Acrivon Therapeutics | Reiterates: Overweight | n/a | $2.41 | - | 2 | Mar 26, 2025 | |
| TARA Protara Therapeutics | Initiates: Overweight | n/a | $5.33 | - | 1 | Mar 14, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Overweight | n/a | $11.86 | - | 5 | Feb 7, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Overweight | n/a | $1.13 | - | 7 | Jan 24, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Overweight | n/a | $23.83 | - | 4 | Oct 7, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Overweight | n/a | $7.05 | - | 5 | Sep 9, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Overweight | n/a | $0.99 | - | 1 | May 15, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Overweight | n/a | $7.70 | - | 5 | Apr 1, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Overweight | $3 | $3.77 | -20.42% | 4 | Nov 22, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Neutral | $5 | $0.98 | +408.85% | 3 | Sep 7, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Overweight | $60 → $38 | $1.85 | +1,954.05% | 1 | Aug 12, 2022 |
ArriVent BioPharma
Dec 23, 2025
Initiates: Overweight
Price Target: n/a
Current: $20.12
Upside: -
Compass Therapeutics
Dec 3, 2025
Initiates: Overweight
Price Target: n/a
Current: $5.37
Upside: -
Ascendis Pharma
Oct 13, 2025
Maintains: Overweight
Price Target: $203 → $254
Current: $213.24
Upside: +19.11%
Context Therapeutics
Oct 2, 2025
Initiates: Overweight
Price Target: n/a
Current: $1.47
Upside: -
IDEAYA Biosciences
Sep 9, 2025
Reiterates: Overweight
Price Target: n/a
Current: $34.57
Upside: -
Replimune Group
Jul 30, 2025
Upgrades: Overweight
Price Target: n/a
Current: $9.72
Upside: -
Kura Oncology
Jun 26, 2025
Reiterates: Overweight
Price Target: n/a
Current: $10.39
Upside: -
Zai Lab
Mar 27, 2025
Reiterates: Overweight
Price Target: n/a
Current: $17.64
Upside: -
Acrivon Therapeutics
Mar 26, 2025
Reiterates: Overweight
Price Target: n/a
Current: $2.41
Upside: -
Protara Therapeutics
Mar 14, 2025
Initiates: Overweight
Price Target: n/a
Current: $5.33
Upside: -
Feb 7, 2025
Reiterates: Overweight
Price Target: n/a
Current: $11.86
Upside: -
Jan 24, 2025
Reiterates: Overweight
Price Target: n/a
Current: $1.13
Upside: -
Oct 7, 2024
Reiterates: Overweight
Price Target: n/a
Current: $23.83
Upside: -
Sep 9, 2024
Reiterates: Overweight
Price Target: n/a
Current: $7.05
Upside: -
May 15, 2024
Reiterates: Overweight
Price Target: n/a
Current: $0.99
Upside: -
Apr 1, 2024
Reiterates: Overweight
Price Target: n/a
Current: $7.70
Upside: -
Nov 22, 2023
Reiterates: Overweight
Price Target: $3
Current: $3.77
Upside: -20.42%
Sep 7, 2023
Reiterates: Neutral
Price Target: $5
Current: $0.98
Upside: +408.85%
Aug 12, 2022
Maintains: Overweight
Price Target: $60 → $38
Current: $1.85
Upside: +1,954.05%